A Study to Assess How Food Affects the Movement of Oral ABBV-101 Through the Body of Healthy Adult Participants
← catalyst calendarSponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Randomized · None · Basic science
Enrollment
17actual
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-03-25 | actual | When the study began enrolling |
| Primary completion | 2025-09-16 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-09-16 | actual | The whole study's end, after follow-up |
| First posted | 2025-03-20 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-10-02 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy Volunteer
Intervention
- Drug: ABBV-101
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants Experiencing Adverse Events
measured Up to approximately 45 days
Maximum Observed Plasma Concentration (Cmax) of ABBV-101
measured Up to approximately 21 days
Time to Cmax (Tmax) of ABBV-101
measured Up to approximately 21 days
Area Under the Plasma Concentration-Time Curve (AUC) of ABBV-101
measured Up to approximately 21 days
Terminal Phase Elimination Half-life (t1/2) of ABBV-101
measured Up to approximately 21 days
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed